The Global Emerging Cancer Diagnostics Market To Take A Big Leap Towards Development

20 Mar 2017

The number of cancer stricken people is escalating gradually as we are headed towards a technologically advanced future. It is estimated that the cancer stricken population will double by 2040. The healthcare industry is investing in the research and development of cancer diagnostics. The emerging cancer diagnostics market is growing at a significant rate with the integration of smart devices with medical devices and advancement of healthcare technologies. The gradual development in the cancer care technologies are developing a concrete platform for further growth of cancer diagnostics market.

Major players in the global emerging cancer diagnostics market are investing in research and development, along with government agencies, and adopting different strategies to expand their business in the market. Becton, Dickinson and Company, one of the key players in the market and a leading global medical technology company, demonstrated its approach “to a synchronized medication management technology platform aimed to help close the communication gaps between different software and devices and optimize interoperability with the EMR systems to deliver a more seamless med management process,” as cited by PR Newswire. “BD's leading Pyxis™ and Alaris™ technologies will be linked throughout the medication management process and interoperable with health IT platforms ? improving the safety and accuracy of medication management workflows, while reducing complexity and cost.”

While some companies are concentrating on developing a sound and synchronized medication management technology, others are innovating systems in medicare to provide free tests for patients. In a similar step, Biocept Collaborated with Catalyst Pharmaceuticals, to provide liquid biopsy testing for small cell lung cancer to patients with Lambert Eaton Myasthenic Syndrome (LEMS), as cited by PR Newswire. According to Biocepts, its “ liquid biopsy tests will be offered by Catalyst Pharmaceuticals at no cost to all patients enrolled in its ongoing Phase III clinical trial designed to demonstrate the safety and efficacy of Firdapse® (amifampridine phosphate) for the treatment of LEMS.”

Taking in account the rapid development taking place in the global emerging cancer diagnostics market, BIS Research has acknowledged the fair share of this market in the healthcare industry and has conducted a research in the emerging cancer diagnostics market. The market research report titled ‘Global Emerging Cancer Diagnostics (Tumor Biomarker Test) Market Analysis & Forecast 2016-2023’ is a detailed analysis of the market, including a thorough analysis of the tests across different regions.
According to the analyst at BIS Research, “The demand for cancer diagnostics tests are increasing every year due to its ease of access and facility. The global emerging cancer diagnostics market has been identified as one of the fastest growing industries, owing to the changing dynamics of the legal and regulatory framework and the intense competitive rivalry among a plethora of public companies.”

The report includes a detailed chapter on the market dynamics, including the key driving and restraining forces, along with viable opportunities for the global emerging cancer diagnostics market through the forecast period. Some of the major players analysed in the report are- Abbott Laboratories, AstraZeneca, Agilent, Becton Dickinson & Co., Biocept Inc. and Cancer Genetics Inc., etc.


Request a Sample


Twitter Feeds